{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:18Z","timestamp":1792112238359,"version":"4.4.0"},"reference-count":11,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Intensive Care Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"\n Objective:<\/jats:title>\n Intravenous (IV) olanzapine could be an alternative to first-generation antipsychotics for the management of agitation in intensive care unit (ICU) patients. We compared the effectiveness and safety of IV olanzapine to IV haloperidol for agitation management in adult patients in the ICU at a tertiary academic medical center.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A retrospective cohort study was conducted. The primary outcome was the proportion of patients who achieved a Richmond Agitation Sedation Scale (RASS) score of < +1 within 4 hours of IV olanzapine or IV haloperidol administration. Secondary outcomes included the proportion of patients who required rescue medications for agitation within 4 hours of initial IV olanzapine or IV haloperidol administration, incidence of adverse events and ICU length of stay.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n In the 192 patient analytic cohort, there was no difference in the proportion of patients who achieved a RASS score of < +1 within 4 hours of receiving IV olanzapine or IV haloperidol (49% vs. 42%, p = 0.31). Patients in the IV haloperidol group were more likely to receive rescue medications (28% vs 55%, p < 0.01). There was no difference in the incidence of respiratory events or hypotension between IV olanzapine and IV haloperidol. Patients in the IV olanzapine group experienced more bradycardia (11% vs. 3%, p = 0.04) and somnolence (9% vs. 1%, p = 0.02) compared to the IV haloperidol group. Patients in the IV olanzapine group had a longer median ICU length of stay (7.5 days vs. 5 days, p = 0.04).<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In this retrospective cohort study, there was no difference in the effectiveness of IV olanzapine compared to IV haloperidol for the management of agitation. IV olanzapine was associated with an increased incidence of bradycardia and somnolence.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/0885066620984450","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T19:43:17Z","timestamp":1610653397000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Retrospective Comparison of the Effectiveness and Safety of Intravenous Olanzapine Versus Intravenous Haloperidol for Agitation in Adult Intensive Care Unit Patients"],"prefix":"10.1177","volume":"37","author":[{"given":"Michelle","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen T.","family":"Yankama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma Julie","family":"Eche","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation and Hematologic Malignancies Program, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen N.","family":"Knoph","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"},{"name":"Department of Pharmacy Practice, MCPHS University, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-1813","authenticated-orcid":false,"given":"Ifeoma Mary","family":"Eche","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"bibr1-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003299"},{"key":"bibr2-0885066620984450","volume-title":"Zyprexa (Package Insert) Indianapolis, Eli Lilly Pharm","author":"Olanzapine (Zyprexa)","year":"2018"},{"key":"bibr3-0885066620984450","unstructured":"Haloperidol (package insert). Haloperidol (Package Inser Schaumburg, Sagent Pharm Inc) Revis January 2018."},{"key":"bibr4-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2012.07.118"},{"key":"bibr5-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2016.08.008"},{"key":"bibr6-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12842"},{"key":"bibr7-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2016.07.033"},{"key":"bibr8-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2107138"},{"key":"bibr9-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.21.2703"},{"key":"bibr10-0885066620984450","first-page":"694","volume":"1","author":"Hodges M","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"bibr11-0885066620984450","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"}],"container-title":["Journal of Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0885066620984450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0885066620984450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0885066620984450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:56:44Z","timestamp":1777503404000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0885066620984450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1177\/0885066620984450"],"URL":"https:\/\/doi.org\/10.1177\/0885066620984450","relation":{},"ISSN":["0885-0666","1525-1489"],"issn-type":[{"value":"0885-0666","type":"print"},{"value":"1525-1489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]}}}